Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (3): 222-227.doi: 10.3969/j.issn.1000-6621.2021.03.006
• Original Articles • Previous Articles Next Articles
ZHANG Li-fan*, MA Hui-min, ZHENG Wen-jie, ZHANG Feng-chun, LIU Xiao-qing()
Received:
2021-01-28
Online:
2021-03-10
Published:
2021-03-03
Contact:
LIU Xiao-qing
E-mail:liuxq@pumch.cn
ZHANG Li-fan, MA Hui-min, ZHENG Wen-jie, ZHANG Feng-chun, LIU Xiao-qing. Analysis of prevention treatment for tuberculosis in tumor necrosis factor antagonist users in some regions of China[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 222-227. doi: 10.3969/j.issn.1000-6621.2021.03.006
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.03.006
患者 序号 | 性 别 | 年龄 (岁) | 诊断 | TNF 拮抗剂 | 应用 激素 | 应用免疫 抑制剂 | 基础病 | T-SPOT. TB检测 | TST 检测 | 结核病 既往史 | 非活动性 肺结核 | 预防性 治疗方案 | 总疗程 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 男 | 50 | RA | 英夫利 西单抗 | 是 | 甲氨蝶呤 | 无 | - | - | 无 | 无 | 异烟肼+ 利福喷丁 | 2个月 |
2 | 女 | 46 | RA | 依那西普 | 是 | 来氟米特 | 无 | - | - | 无 | 无 | 异烟肼+ 利福平 | 8个月 |
3 | 女 | 46 | RA | 依那西普 | 是 | 甲氨蝶呤 | 无 | - | - | 无 | 无 | 异烟肼 | 4个月 |
4 | 女 | 61 | RA | 依那西普 | 是 | 甲氨蝶呤; 来氟米特 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 不详 |
5 | 男 | 53 | RA | 依那西普 | 是 | 甲氨蝶呤; 来氟米特 | 无 | - | - | 无 | - | 异烟肼+ 利福平+ 乙胺丁醇+ 吡嗪酰胺 | 1个月 |
6 | 女 | 61 | RA | 依那西普 | 否 | 无 | 糖尿病 | - | - | 无 | 无 | 异烟肼 | 18个月 |
7 | 男 | 31 | AS | 依那西普 | 否 | 无 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 1个月 |
8 | 男 | 55 | AS | 依那西普 | 否 | 柳氮磺 胺吡啶 | 无 | - | 阳性 | 无 | 无 | 异烟肼 | 不详 |
9 | 女 | 24 | AS | 依那西普 | 否 | 无 | 无 | - | - | 无 | 无 | 异烟肼 | 1个月 |
10 | 男 | 53 | AS | 依那西普 | 否 | 无 | 无 | 阴性 | - | 无 | 无 | 异烟肼 | 1个月 |
11 | 男 | 20 | AS | 依那西普 | 是 | 柳氮磺 胺吡啶 | 无 | 阴性 | 阳性 | 无 | 无 | 异烟肼 | 不详 |
12 | 女 | 19 | AS | 依那西普 | 是 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | - | - | 无 | 无 | 异烟肼+ 利福平+ 乙胺丁醇+ 吡嗪酰胺 | 6个月 |
13 | 男 | 45 | AS | 依那西普 | 是 | 柳氮磺胺吡啶 | 无 | - | - | 无 | - | 不详 | 不详 |
14 | 男 | 33 | AS | 依那西普 | 否 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 4个月 |
15 | 男 | 28 | AS | 依那西普 | 否 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | 阳性 | - | 无 | - | 异烟肼+ 利福平 | 24个月 |
[1] |
LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis, 2017,17(10):e327-e333. doi: 10.1016/S1473-3099(17)30248-7.
doi: 10.1016/S1473-3099(17)30248-7 URL pmid: 28495525 |
[2] |
Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol, 2007,34(4):706-711.
URL pmid: 17309133 |
[3] |
Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum, 2003,48(8):2122-2127. doi: 10.1002/art.11137.
doi: 10.1002/art.11137 URL pmid: 12905464 |
[4] |
Koike R, Takeuchi T, Eguchi K, et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol, 2007,17(6):451-458. doi: 10.1007/s10165-007-0626-3.
doi: 10.1007/s10165-007-0626-3 URL |
[5] |
Favalli EG, Caporali R, Sinigaglia L, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology Ⅱ. Safety. Clin Exp Rheumatol, 2011,29(3 Suppl 66):S15-S27.
URL pmid: 21906424 |
[6] |
Bombardier C, Hazlewood GS, Akhavan P, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part Ⅱ safety. J Rheumatol, 2012,39(8):1583-1602. doi: 10.3899/jrheum.110207.
doi: 10.3899/jrheum.120165 URL |
[7] |
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 2005,60(10):800-805. doi: 10.1136/thx.2005.046797.
doi: 10.1136/thx.2005.046797 URL pmid: 16055611 |
[8] | Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly, 2007,137(43/44):620-622. |
[9] | Center for Disease Control and Prevention. Latent tuberculosis infection: A guide for primary health care providers[EB/OL].[2021-01-28]. https://www.cdc.gov/tb/publications/ltbi/pdf/ltbibooklet508.pdf. |
[10] |
Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J, 2015,46(6):1563-1576. doi: 10.1183/13993003.01245-2015.
doi: 10.1183/13993003.01245-2015 URL pmid: 26405286 |
[11] | 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识. 中华风湿病学杂志, 2013,17(8):508-512. doi: 10.3760/cma.j.issn.1007-7480.2013.08.002. |
[12] |
Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 2002,168(9):4620-4627. doi: 10.4049/jimmunol.168.9.4620.
doi: 10.4049/jimmunol.168.9.4620 URL pmid: 11971010 |
[13] |
Vila-del Sol V, Díaz-Muñoz MD, Fresno M. Requirement of tumor necrosis factor alpha and nuclear factor-kappaB in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J Leukoc Biol, 2007,81(1):272-283. doi: 10.1189/jlb.0905529.
URL pmid: 17035338 |
[14] |
Nocturne G, Boudaoud S, Pascaud J, et al. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J Autoimmun, 2017,80:56-64. doi: 10.1016/j.jaut.2017.02.001.
doi: 10.1016/j.jaut.2017.02.001 URL pmid: 28214146 |
[15] |
Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest, 2009,119(5):1079-1082. doi: 10.1172/jci39143.
doi: 10.1172/jci39143 URL pmid: 19422095 |
[16] |
Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum, 2004,50(2):372-379. doi: 10.1002/art.20009.
doi: 10.1002/art.20009 URL pmid: 14872478 |
[17] |
Wallis RS, Broder M, Wong J, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis, 2004,39(8):1254-1255. doi: 10.1086/424455.
doi: 10.1086/424455 URL pmid: 15486857 |
[18] |
Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum, 2005,52(7):1986-1992. doi: 10.1002/art.21137.
doi: 10.1002/art.21137 URL pmid: 15986370 |
[19] |
Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med, 2016,12(3):1693-1704. doi: 10.3892/etm.2016.3548.
doi: 10.3892/etm.2016.3548 URL pmid: 27588089 |
[20] |
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody)versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase Ⅲ trial. ATTRACT Study Group. Lancet, 1999,354(9194):1932-1939. doi: 10.1016/s0140-6736(99)05246-0.
doi: 10.1016/s0140-6736(99)05246-0 URL pmid: 10622295 |
[21] |
Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum, 2005,52(6):1766-1772. doi: 10.1002/art.21043.
doi: 10.1002/art.21043 URL pmid: 15934089 |
[22] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management: annex 3: values and preferences for the management of latent tuberculosis infection: survey of populations affected by the recommendations. Geneva: World Health Organization, 2018. |
[23] | 边赛男, 刘晓清. γ-干扰素释放试验在免疫功能抑制人群中诊断结核分枝杆菌感染的应用. 中华实验和临床感染病杂志(电子版), 2017,11(2):117-120. doi: 10.3877/cma.j.issn.1674-1358.2017.02.003. |
[24] |
Grzybowski S, Fishaut H, Rowe J, et al. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis, 1971,104(4):605-608. doi: 10.1164/arrd.1971.104.4.605.
doi: 10.1164/arrd.1971.104.4.605 URL pmid: 5094062 |
[25] |
Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. Am Rev Respir Dis, 1988,137(4):805-809. doi: 10.1164/ajrccm/137.4.805.
doi: 10.1164/ajrccm/137.4.805 URL pmid: 3354985 |
[26] |
This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med, 2000,161(4 Pt 2):S221-S247. doi: 10.1164/ajrccm.161.supplement_3.ats600.
doi: 10.1164/ajrccm.161.supplement_3.ats600 URL pmid: 10764341 |
[27] |
Zhang CY, Zhao F, Xia YY, et al. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. Infect Dis Poverty, 2019,8(1):7. doi: 10.1186/s40249-019-0515-y.
doi: 10.1186/s40249-019-0515-y URL pmid: 30654836 |
[28] |
Xin H, Zhang H, Yang S, et al. 5-Year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis, 2020,70(5):947-950. doi: 10.1093/cid/ciz581.
doi: 10.1093/cid/ciz581 URL pmid: 31253988 |
[29] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[30] |
Gao L, Li X, Zhang H, et al. Incidence of active tuberculosis in rural China-Authors’ reply. Lancet infect Dis, 2018,18(2):145-146. doi: 10.1016/S1473-3099(18)30022-7.
doi: 10.1016/S1473-3099(18)30022-7 URL pmid: 29412964 |
[31] |
Wong SH, Gao Q, Tsoi KK, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax, 2016,71(1):64-72. doi: 10.1136/thoraxjnl-2015-207811.
doi: 10.1136/thoraxjnl-2015-207811 URL pmid: 26659461 |
[32] |
Puri AS, Desai D, Sood A, et al. Infliximab-induced tuberculosis in patients with UC: Experience from India-a country with high prevalence of tuberculosis. J Gastroenterol Hepatol, 2017,32(6):1191-1194. doi: 10.1111/jgh.13669.
doi: 10.1111/jgh.13669 URL pmid: 27893931 |
[33] |
Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adali-mumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol, 2020,115(3):340-349. doi: 10.14309/ajg.0000000000000527.
doi: 10.14309/ajg.0000000000000527 URL pmid: 32032073 |
[34] |
Ye L, Chapman TP, Wen Z, et al. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Aliment Pharmacol Ther, 2021,53(3):390-399. doi: 10.1111/apt.16130.
doi: 10.1111/apt.16130 URL pmid: 33314259 |
[35] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[1] | MA Yan, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317. |
[2] | DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321. |
[3] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[4] | GE Qi-ping, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334. |
[5] | ZHANG Li-jie, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340. |
[6] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui, LI Cheng-cheng. Analysis of CT features of drug-resistant pulmonary tuberculosis with cavity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 341-345. |
[7] | YU Shan, LI Zhi-ming, XU Chun-xia, WANG Tao. Analysis of risk factors associated with false negative results of interferon-gamma release assays on peripheral blood from tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 346-351. |
[8] | LIU Ting, WANG Liang, YANG Mei. The study on the anti-tuberculosis activity of polymorphonuclear cell from peripheral blood of patients with multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 352-356. |
[9] | ZHANG Chen-chen, TAN Wei-guo, GUO Hui-xin, HUANG Xin-chun, CHEN Yan-mei, WEI Wen-jing. The effect of Mycobacterium tuberculosis infection on sputum flora structure [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 357-363. |
[10] | BAI Hua, GUO Jing-wei, HU Pei-lei, YI Song-lin, WEN Jia, LIU Feng-ping, TAN Yun-hong, BAI Li-qiong. Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Hu’nan Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 364-369. |
[11] | WANG Huan, SHEN Xin, CHEN Jing, XIA Zhen, XU Biao, YUAN Zheng-an. Analysis of the epidemiological characteristics of pulmonary tuberculosis among migrants in Shanghai from 2008 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 370-377. |
[12] | MA Zhi-tao, WANG Na, LYU Yang, HU Wei-hong, CHEN Chang, HE Fan, SHEN Xin, LIU Xiao-feng. The research on psychological status of pulmonary tuberculosis patients and influencing factors in Baoshan District, Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 378-384. |
[13] | LI Zhi-hong, GU Kan-kai, YAO Jing, ZHANG Huai-qing, HAN Zhi-ying, SHEN Xin, CHEN Jing, SHEN Bing. Analysis of screening of close contacts of a tuberculosis patient in a kindergarten in downtown Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 385-390. |
[14] | LIU Zhen-jiang, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[15] | ZHOU Shuang, CHEN Nan, ZHU Kun, JIANG Hui, YANG Lei, DU Jian. Investigation of the experience of tuberculosis patients for follow up using the internet platform [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 398-403. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||